Updated:
MediWound
MediWound is an Israeli biotech led by CEO Ofer Gonen, maker of FDA-approved NexoBrid, an enzyme-based burn treatment derived from pineapple stems.
MediWound
MediWound operates as a publicly traded biopharmaceutical company headquartered in Yavne, Israel, with Ofer Gonen serving as Chief Executive Officer. Its founding traces the repurposing of an enzymatic mixture derived from the stem of the pineapple plant — a biological mechanism observed in nature and industrialized for debridement, the removal of dead tissue from wounds. The company's disclosure regime follows the Tel Aviv Stock Exchange and Nasdaq listing standards, not a family-office template: it reports to public shareholders and regulatory agencies rather than a single-family principal. The firm's strategy concentrates on enzymatic wound care across two verticals: burn treatment and chronic wound management. Its flagship product, NexoBrid, secured FDA approval in December 2022 for eschar removal in adults with deep partial-thickness and full-thickness thermal burns — a decision that unlocked the US market alongside existing European and international authorizations. A second asset, EscharEx, targets venous leg ulcers and diabetic foot ulcers, two chronic wound categories where standard-of-care sharp debridement remains painful and operator-dependent. MediWound's inventory model is distinct: it manufactures at a single facility in Israel and sells to governments for emergency stockpiling — the Biomedical Advanced Research and Development Authority (BARDA) placed orders for US preparedness — alongside direct hospital sales through its own sales force and commercial partners. In September 2023, the company secured an expanded $50 million contract with the US Department of Defense for NexoBrid procurement (per the firm, September 2023). Geographic revenue spans North America, Europe, the Middle East, and Asia-Pacific through licensing agreements with Vericel, Teva, and others. The company reported 85 full-time employees at year-end 2023, according to its public filings, with R&D occupying a majority of headcount. Governance sits with a board of directors chaired by Stephen T. Wills, former CFO of Parexel; the structure lacks a controlling family shareholder, distinguishing it from single-family-office biotech plays. In May 2024, MediWound announced that the European Medicines Agency accepted its pediatric investigation plan for NexoBrid, a procedural step that extends the product lifecycle into burn-injured children — a historically underserved cohort in wound care trials (per the firm, May 2024). The company's Israeli manufacturing site also produces active pharmaceutical ingredient for its own pipeline and, under contract, for third-party biotech firms — a second revenue stream that capitalizes on excess capacity. The structural differentiator is a dual monopoly of source and function. MediWound controls the active pharmaceutical ingredient — a bromelain-rich enzyme mix — derived from a singular plant input, and the final drug product is a biologic approved under a Biologics License Application rather than a generic-able small molecule. This makes manufacturing replication by a competitor legally and technically prohibitive, creating a durable barrier long after patent expiration. The company is not a family office, does not manage third-party capital, and does not participate in fund structures; it is an operating company that allocates its own balance sheet and public-market proceeds toward clinical trials and commercialization.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
Middle East
Country
Israel
City
Yavne
Corporate office
Yavne, Israel
Principals
Ofer Gonen
Chief Executive Officer
Sector focus
Frequently asked questions
What is MediWound's core technology platform?
MediWound's products rely on a concentrate of proteolytic enzymes extracted from pineapple plant stems, known as bromelain. The company formulates this mixture to selectively dissolve non-viable burn and wound tissue while preserving healthy skin. No other commercial product uses the same enzymatic mechanism for debridement at scale, and the active ingredient remains proprietary in formulation and manufacturing process.
How does MediWound generate revenue from its burn treatment?
Revenue derives from three channels: direct hospital sales through MediWound's own sales force in select territories, government emergency stockpiling contracts — notably with BARDA and the US Department of Defense — and licensing royalties from commercial partners such as Vericel in North America and Teva Pharmaceuticals in certain markets. Stockpile orders are lumpy and tied to government procurement cycles, while hospital sales follow the adoption curve of a niche acute-care biologic.
What does the FDA approval of NexoBrid mean for the company's moat?
FDA approval in December 2022 validated NexoBrid's clinical profile in the largest single-country burn-care market and erected a substantial regulatory barrier for any competitor trying to enter the same enzymatic-debridement category. The approval also triggered milestone payments from licensing partners and expanded the addressable market beyond Europe, where MediWound previously held a centralized marketing authorization. A competitor would need to replicate the biologic manufacturing process and run parallel clinical programs, a timeline measured in years rather than quarters.
What is EscharEx, and how does it fit MediWound's pipeline?
EscharEx is MediWound's Phase III-stage product for chronic wound debridement, including venous leg ulcers and diabetic foot ulcers. It uses an enzyme formulation related to NexoBrid's but optimized for the lower-acuity, repeat-treatment setting of outpatient wound care. If approved, it would open a recurring-revenue opportunity distinct from the episodic burn-treatment market, where a single application usually suffices.
Is MediWound a family office or does it manage private capital?
MediWound is not a family office and does not manage external investor capital. It is a publicly traded biopharmaceutical company dual-listed on Nasdaq and the Tel Aviv Stock Exchange. It funds operations through equity offerings, debt, and non-dilutive government contracts. No single family or principal controls a majority of the outstanding shares, and governance follows public-company fiduciary norms.
Which agencies stockpile MediWound's products, and why?
The Biomedical Advanced Research and Development Authority (BARDA) within the US Department of Health and Human Services and the US Department of Defense are the primary stockpiling customers. NexoBrid is considered a medical countermeasure for mass-casualty burn incidents, including radiological or explosive events. This aligns the company's revenue base partly with biodefense preparedness budgets rather than purely commercial reimbursement dynamics.
What manufacturing advantages does MediWound hold?
MediWound owns and operates a dedicated manufacturing plant in Yavne, Israel, designed to produce the active pharmaceutical ingredient and finished NexoBrid vials under biologic-grade standards. The plant also contracts its capacity to other biotech firms for enzyme-based manufacturing. Owning the facility — rather than outsourcing to a contract manufacturing organization — gives MediWound direct control over cost of goods and supply-chain security for a biologic product where process is inseparable from product quality.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: